STOCK TITAN

Emergent BioSolutions Inc. - $EBS STOCK NEWS

Welcome to our dedicated page for Emergent BioSolutions news (Ticker: $EBS), a resource for investors and traders seeking the latest updates and insights on Emergent BioSolutions stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Emergent BioSolutions's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Emergent BioSolutions's position in the market.

Rhea-AI Summary
Emergent BioSolutions Inc. appoints Joseph C. Papa as president and CEO to focus on public health protection, growth, and debt reduction. The company highlights key achievements in 2023, including product launches, FDA approvals, and financial improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.29%
Tags
management acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) secures a $235.8 million contract with the U.S. Department of Defense to supply BioThrax for anthrax prevention. The contract includes a five-year base agreement and an additional five-year option, highlighting the importance of Emergent's medical countermeasures portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences acquisition
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) receives a $75 million contract option from BARDA for newly licensed anthrax vaccine CYFENDUS™. The vaccine was approved by the FDA in July 2023 and is aimed at addressing the national security threat posed by anthrax. Deliveries are expected to be completed by the end of the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) received a notice from the NYSE regarding non-compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the SEC. Emergent has six months to file the Form 10-Q and regain compliance. The company is working to quantify and evaluate the impact of past period state deferred tax liability and income tax benefits on its reporting, which is affecting its ability to provide a complete estimate of its results of operations for the three- and nine-month periods ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) reported Q3 2023 total revenues of $271M, a pre-tax loss of $(266)M, and adjusted EBITDA of $20M. The company updated its FY 2023 guidance. Key highlights include FDA approval of CYFENDUSTM, a 10-year contract for EbangaTM, and the over-the-counter launch of NARCAN® Nasal Spray. The company also completed the FDA inspection of its Camden facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
Rhea-AI Summary
Emergent BioSolutions Inc. has rescheduled its conference call to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. The call will now take place on Wednesday, November 8, at 5:00 pm eastern time. Participants can access the call via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
-
Rhea-AI Summary
Emergent BioSolutions to host conference call to discuss Q3 2023 financial results and business developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
-
Rhea-AI Summary
Emergent partners with Emmitt Smith to raise awareness of opioid dangers and promote NARCAN® Nasal Spray
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
partnership acquisition
Rhea-AI Summary
Emergent BioSolutions announces appointment of Neal Fowler and Don DeGolyer to its Board of Directors, bringing extensive biopharmaceutical industry and sales experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
management acquisition
Emergent BioSolutions Inc.

NYSE:EBS

EBS Rankings

EBS Stock Data

298.69M
51.22M
1.88%
79.22%
10.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG

About EBS

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent